Thanks @AATSHQ for highlighting our work @MayoClinic
We add to evidence that stage I NSCLC is not always βlow riskβ
In pts with resected path stage I NSCLC <3cm, readily available features (SUVmax, LVI, VPI) were each assoc with worse outcomes and their effects were cumulative
We add to evidence that stage I NSCLC is not always βlow riskβ
In pts with resected path stage I NSCLC <3cm, readily available features (SUVmax, LVI, VPI) were each assoc with worse outcomes and their effects were cumulative
New in #JTCVS: The additive effect of high-risk tumor features on long-term survival and recurrence in pathologic stage I #NSCLC. Learn more in this editor's choice article for free until 11/30: hubs.la/Q04CVM5s0View quoted post on X
@LFTapias @MayoClinicCVS